alexa Slow Down That Racing Heart: A Comparison of Ivabradine

Research & Reviews: Journal of Hospital and Clinical Pharmacy
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Review Article

Slow Down That Racing Heart: A Comparison of Ivabradine Versus Digoxin for the Treatment of Chronic Heart Failure

Lillian Smith1, Juan Mosley1*, Megan Ford2, Jonathan Courtney2, Chase Stefanelli2

1Department of Pharmacy Practice, Florida A&M University, USA

2Florida Agricultural and Mechanical University, USA

*Corresponding Author:
Juan Mosley
Assistant Professor of Pharmacy Practice
College of Pharmacy and Pharmaceutical Sciences
153 W. Woodruff Ave
Crestview, FL, USA
Tel: (850) 689-4006
Fax: (850) 689-7870
E-mail: [email protected]

Received date: 13/04/2016; Accepted date: 04/05/2016; Published date: 11/05/2016

 

Abstract

Background: Heart failure (HF) is a chronic condition in which the heart cannot pump blood effectively enough to meet the demands of the body. Pharmacological treatment focuses on reducing the workload of the heart, reducing heart rate, increasing cardiac output, decreasing edema, and reducing mortality. Angiotensin converting enzyme inhibitors (ACE-I), angiotensin receptor blockers (ARBs), aldosterone antagonists, and beta blockers are medication classes commonly used in the treatment of heart failure. Other treatment options include the use of digoxin and ivabradine. Objective: Digoxin and ivabradine are both utilized to further reduce heart rate uncontrolled by the standard of care. However, digoxin and ivabradine differ based on mechanism of action, effect on left ventricular ejection fraction, drug interactions, costs, and adverse effects. Discussion: Digoxin and Ivabradine have both been shown effective at lowering heart rate and treating some of the symptoms associated with chronic heart failure. Digoxin has been on the market longer, contributing to a more extensive knowledge of its safety and efficacy as compared to ivabradine. However, the SHIFT trial provides evidence that ivabradine can reduce hospitalizations. There are fewer drug interactions associated with ivabradine and drug level monitoring is not required. Nevertheless, ivabradine adverse effects may significantly impact heart failure patients. Conclusion: Ivabradine is appealing with respect to its ability to reduce hospitalizations in patients with heart failure, as well as its ease of dosing and monitoring. However, due to its increased cost and lack of extensive use, digoxin may provide a more cost effective option for many patients.

Keywords

Share This Page

Additional Info

Loading
Loading Please wait..
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords